Axonics Modulation Technologies is looking to challenge major players in the field of neuromodulation. The Irvine, Calif.-based company is developing novel, implantable sacral nerve neuromodulation tech to treat patients with urinary and bowel dysfunction disorders, with hopes that the platform will be expandable into other clinical indications in the future.
With technology licensed from the Alfred Mann Foundation, the company’s Axonics r-SNM system features a miniaturized rechargeable implantable stimulator it claims will work for at least 15 years,. The system also features a charging system designed for quick charge times and a user-friendly remote control and programming interface.
Axonics has already made some bold steps against its competition – Medtronic’s InterStim device and StimGuard – having won approval in Canada and Europe for the system with indications for treating overactive bladder, urinary retention and fecal incontinence.
–Fink Densford, Associate Editor